Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues

p53 Alteration and Chromosomal Instability in Prostatic High-Grade Intraepithelial Neoplasia and Concurrent Carcinoma: Analysis by Immunohistochemistry, Interphase In Situ Hybridization, and Sequencing of Laser-Captured Microdissected Specimens

“…Hall et al (44) found complete agreement between IHC and TP53 SSCP analysis. Wertz et al (48) reported 85% overall agreement between the two methods, whereas the concordance was 76.7% by Salem et al (7). In one of our cases, a point mutation has been seen at Codon 273, changing the amino acid from arginine to cystine.…”

“…Still, IHC does not detect all alteration that may affect p53 function, such as loss of heterozygosity at the p53 locus, nonsense or splice site mutations, or amplification of the MDM-2 gene, but all of these are very rare in prostate cancer. Generally, a good correlation between p53 alteration detected by IHC and molecular studies has been noted in prostate cancer (4,7,44,48,49). Hall et al (44) found complete agreement between IHC and TP53 SSCP analysis.…”

Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression

“…As functionally relevant mutations of the TP53 gene mostly result in an abnormal stabilization of the mutated protein, its accumulation can be visualized by immunohistochemistry, whereas the wildtype p53 escapes detection due to the short half-life time. In PC, p53 immunohistology was proven to correlate well with TP53 gene mutations (Wertz et al, 1996). Nonetheless, TP53 mutations seem to be a late event in PC progression and are identified mainly in poorly differentiated and metastatic tumours, indicating an association with poor prognosis (Visakorpi et al, 1992;Bookstein et al, 1993;Navone et al, 1993;Eastham et al, 1995;Kubota et al, 1995;Shurbaji et al, 1995) The rates of approximately 30% and 40% of p53 positivity in advanced PC before and after ADT, respectively, are within the range of results for abnormal p53 accumulation published in the literature.…”

Differences in Gene Expression in Muscle– Invasive Bladder Cancer: A Comparison of Italian and American Patients

“…A 1:1 monoclonal antibody cocktail composed of DO1 (Oncogene Science, Cambridge, Mass.) at a 1:100 dilution and DO7 (Novacastro, Newcastle, UK) at 1:200 was employed according to our published protocol [9]. Subsequently, p53 staining was repeated for the entire group of tumors using Pab 1801 (Oncogene Science) at a 1:100 dilution overnight at 4°C.…”

“…Tissue was considered to be p53–positive if >20% of tumor cell nuclei were immunopositive. This cutoff was set at 4 times higher than found for the negative control cell line (LNCaP, which has wt p53 ) as reported in our previously published work [9]. The cutoff points for Rb and Bcl–2 were set by evaluating the maximum number of cells that stained positively in the negative cell line controls and setting the cutoff above that number.…”